| Sign In to gain access to subscriptions and/or personal tools. |
Differential Expression of COX-1 and COX-2 in the Gastrointestinal Tract of the RatDepartment of Pathology, Safety Assessment, GlaxoSmithKline Research and Development Ltd., Ware, Herts SG12 0DP, United Kingdom Correspondence: Address correspondence to: Richard Haworth, Department of Pathology, Safety Assessment, GlaxoSmithKline Research and Development Ltd, Park Road, Ware, Herts SG12 0DP, United Kingdom; e-mail:richard.i.haworth{at}gsk.com
The aim of this study was to use immunohistochemistry with morphometry to investigate COX-1 and COX-2 expression in the normal rat gastrointestinal (GI) tract and examine if sites of ulceration previously observed with long-term COX-2 inhibitor administration in mice correlate with differential COX-1/COX-2 expression. COX-2 positive cells were observed predominantly in the apical lamina propria of intestinal villi with fewer cells in the mucosal epithelium. The highest level of COX-2 expression was observed at the ileocaecal junction (ICJ). COX-2 expression was also present in parasympathetic ganglia of the submucosa and muscularis. In the stomach, the highest grade of COX-2 expression was observed in the apical lamina propria of the fundus adjacent to the junctional ridge. In contrast, COX-1 positive cells within the lamina propria were evenly distributed along the GI tract but were present in higher numbers than COX-2 positive cells. The mean level of COX-1 expression at the ICJ was not significantly different from the ileum and caecum. Evidence that the highest level of COX-2 expression in normal rats is located on the ileal side of the ICJ provides the first mechanism to explain spontaneous ulceration and perforation of the distal ileum in COX-2–/– animals.
Key Words: Rat COX-1 COX-2 immunohistochemistry NSAID intestine ileocaecal junction Abbreviations: COX, cyclooxygenase GI, gastrointestinal ICJ, ileocaecal junction LPS, lipopolysaccharide NSAID, nonsteroidal antiinflammatory drug PGE, prostaglandin-E PGI, prostaglandin-I
Toxicologic Pathology, Vol. 33, No. 2,
239-245 (2005) |
|
|||

